Alembic Pharmaceuticals Limited has informed the Exchange about Credit Rating
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received a reaffirmation of its credit rating from CRISIL at AA+/Stable on its total bank loan facilities. The rated amount has been enhanced from Rs. 600 crore to Rs. 800 crore, though the company clarified that its overall borrowing limit remains unchanged. The enhanced limit is spread across six banks — HDFC Bank (Rs. 200 crore), SBI (Rs. 200 crore), Kotak Mahindra Bank (Rs. 100 crore), HSBC (Rs. 100 crore), Axis Bank (Rs. 100 crore), and Citibank (Rs. 100 crore). AA+ is a high investment-grade rating, indicating strong financial health and low default risk.
This is a neutral-to-positive signal for shareholders. The AA+/Stable rating reaffirmation reflects continued lender confidence in Alembic Pharma's financial strength. The expanded rated facility headroom (from Rs. 600 Cr to Rs. 800 Cr) gives the company greater flexibility, even though actual borrowing limits are unchanged. No immediate share price catalyst, but it underscores the company's strong credit profile.